Neurocrine Bio. (NBIX) Won't Have to Contract Aggressively in 2027 - Stifel
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $183.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented, "Today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
